|
KMID : 1024720170070020052
|
|
Geriatric Rehabilitation
2017 Volume.7 No. 2 p.52 ~ p.58
|
|
|
Current Developing or Suggested Medication for Sarcopenia
|
|
Kim Don-Kyu
|
|
|
Abstract
|
|
|
|
Sarcopenia is a geriatric syndrome which is characterized by a deterioration of muscle mass leading to a gradual decline in strength and function. The causes of sarcopenia are multifactorial, such as disuse or immobility, hormonal or endocrine factors, inflammation and nutritional deficiencies, or disease related factors. Resistance training combined with protein or amino acid-containing supplements is well accepted management to prevent and treatment of sarcopenia. Since sarcopenia is largely associated with various molecular mediators affecting muscle metabolism and degeneration/regeneration of muscle, the mechanisms responsible for these changes present therapeutic targets for drug development. In this paper, we will review recent targeted therapeutic medication of sarcopenia or other muscle wasting syndromes and the current understanding of how can these drugs or hormones contribute positively or negatively on sarcopenia and muscle wasting syndromes.
|
|
|
KEYWORD
|
|
|
Sarcopenia, Muscle wasting syndrome, Vitamin D, Hormones, Myostatin inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|